GENERIC PHARMACEUTICALS Sample Clauses

GENERIC PHARMACEUTICALS. Customer agrees to fully participate in McKesson's Select Generics Program through its auto-substitution feature and to thereby designate this program as Customer's primary source of generic pharmaceuticals. In consideration for the above commitments, McKesson will extend to Customer McKesson Select Generics contract pricing in accordance with the attached. This contract is based upon McKesson Select Generics Program pricing less [+]%. Prices are subject to change; provided however, the contract discount percentage made available under this Agreement will remain the same. A quarterly rebate shall be paid to Customer in accordance with the following schedule based on such above- specified participation: Quarterly McKesson Select Generics Volume (net of Quarterly Rebate % on Net returns, allowances and rebates)McKesson Select Generics Purchases ------------------------------------------------------------------ [+] Customer shall be rebated at [+]% for the [+] ([+]) months of this Agreement and thereafter rebated at the earned rate based on actual quarterly purchases. The rebate check will be due to Customer no later than the 30th of the month following the end of the quarter. A [+]% penalty will be paid to Customer on rebate payments received after the applicable due date as defined above.
Sample 1Sample 2
AutoNDA by SimpleDocs
GENERIC PHARMACEUTICALS. McKesson shall pay to Phar-Mor an annual guaranteed rebate based on Phar-Mor's participation in McKesson's Select Generics Program. In order to qualify as participation hereunder, all generic pharmaceuticals purchased by Phar-Mor pharmacies shall be required to be purchased through McKesson's Select Generics Program. Provided Phar-Mor's participation meets the percentage levels as specified below in any year, the guaranteed rebate schedule shall be as follows: Select Generics Rebate Schedule % of Select Generics to Total Rx Rebate ---------------------------------------------------------------------- (*) (*) (*) (*) (*) (*) (*) (*) (*) (*)
Sample 1
GENERIC PHARMACEUTICALS. Customer agrees to fully participate in McKesson's OneStop Generics Program through its auto-substitution feature and to thereby designate this program as Customer's primary source of generic pharmaceuticals. A quarterly rebate shall be paid to Customer in accordance with the following schedule based on such participation: Quarterly McKesson OneStop Generics Purchases as a Percentage of Total Rx Purchases (All Purchases net of returns, allowances, rebates Quarterly Rebate % on Net and all credits and adjustments issued McKesson OneStop Generics Purchases and exclusive of drop shipped purchases) (Rebate amounts are not cumulative) *Notwithstanding anything in the foregoing, in order to qualify for the highest rebate percentage on the above-specified McKesson OneStop Generics rebate schedule (XX%), Customer must attain the specified minimum McKesson OneStop Generics to Rx Product purchases ratio of XX% and must also purchase annualized McKesson OneStop Generics volume of $XX. If Customer fails to meet the above-specified $XX purchase volume threshold, the XX rebate percentage tier shall not apply. For example, if the McKesson OneStop Generics to Rx Product purchases ratio is XX% but the annualized quarterly volume is $XX, Customer would qualify for a XX% rebate.
Sample 1
GENERIC PHARMACEUTICALS. Retailer will pay a purchase price for all generic pharmaceuticals purchased under this Agreement at the price applicable under Prime Supplier’s SynerGx generic pharmaceuticals program. The availability and terms of Prime Supplier’s generic pharmaceuticals program to Retailer may change from time to time based on certain volume thresholds. Subject to certain generic purchasing volumes being met by the Company (including the volume of its participating affiliated retailers), the Company shall pay Retailer a rebate equal to [*] percent ([*]%) of the price for Primary SynerGx generic pharmaceuticals purchased and paid for by Retailer under such program. If the volume thresholds are not met, no rebate shall apply. In addition, no rebate shall be payable if this Agreement has been terminated by the Company prior the end of the rebate period or if the Prime Supplier Agreement has been terminated prior to the end of the rebate period. The rebate, as applicable, shall be paid thirty (30) days after the end of each calendar month. The Company may apply the rebate to any amounts owed [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. by Retailer to the Company. Prime Supplier has agreed that it will provide price protection for any generic product Prime Supplier substitutes with a higher priced generic pharmaceutical product (excluding manual overrides by the Company or by Retailer) as a result of Prime Supplier’s fault in availability.
Sample 1
GENERIC PHARMACEUTICALS. Medical Group shall use best efforts to prescribe or authorize the substitution of generic pharmaceuticals when appropriate and shall cooperate with Plan formularies and state and federal requirements regarding the substitution of generic pharmaceuticals. This provision shall not be interpreted to interfere with Medical Group's independent medical judgment.
Sample 1
GENERIC PHARMACEUTICALS. Horizon agrees that upon commencement of the term of this Agreement to participate in McKesson's Select Generics Program through its auto-substitution feature and to thereby designate this program as Horizon's primary source of generic pharmaceuticals. A quarterly rebate shall be paid to Horizon in accordance with the following matrix based on such participation: REBATE UNDER [REDACTED - CONFIDENTIAL REBATE UNDER [REDACTED - CONFIDENTIAL TREATMENT] PAYMENT TERMS TREATMENT] PAYMENT TERMS [redacted - Confidential Treatment] [redacted - Confidential Treatment]00% [redacted - Confidential Treatment]00% [redacted - Confidential Treatment] [redacted - Confidential Treatment]00% [redacted - Confidential Treatment]00% [redacted - Confidential Treatment] [redacted - Confidential Treatment]00% [redacted - Confidential Treatment]00% [redacted - Confidential Treatment] [redacted - Confidential Treatment]00% [redacted - Confidential Treatment]00% [redacted - Confidential Treatment] [redacted - Confidential Treatment]00% [redacted - Confidential Treatment]00%
Sample 1

Related to GENERIC PHARMACEUTICALS

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Product The term “

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Competitive Products Competitive Products" means products that serve the same function as, or that could be used to replace, products the Company provided to, offered to, or was in the process of developing for a present, former, or future possible customer/partner at any time during the twelve (12) months immediately preceding the last day of Participant's employment (or at any time during Participant's employment if Participant was employed for less than 12 months), with which Participant had direct responsibility for the sale or development of such products or managing those persons responsible for the sale or development of such products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!